Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia There is currently no consensus on the optimal treatment of T-cell large granular lymphocyte (T-LGL) leukemia. Conventional treatment including oral methotrexate, cyclophosphamide and cyclosporine may be effective. 1 However, once the usage of these drugs is stopped, relapses are very frequent. Therefore, a drawback of conventional drugs is the long-term treatment. In fact, it has been suggested that therapy should last indefinitely in responders. 1 Continuous immunosuppression is worrisome, and secondary malignancies have been reported in T-LGL leukemia patients on prolonged treatment with methotrexate and cyclosporine. 2 A finite treatment giving a durable remission is an important goal in leukemia therapy. We have previously reported the efficacy of the regimen FND (fludarabine intravenously, 25 mg/ m 2 /day Â 3; mitoxantrone intravenously, 10 mg/m 2 /day Â 1; dexamethasone orally, 20 mg/day Â 5; repeated every 4 weeks for six courses with cotrimoxazole prophylaxis) in inducing remissions in therapy-refractory T-LGL leukemia. 3 An update of that series of nine patients at a median follow-up of 71 (12-83) months showed that two patients were in continuous remission for 6 and 7 years, without additional maintenance treatment.
Based on these results, three patients with newly diagnosed T-LGL leukemia were given FND as first-line treatment. The diagnosis was based on the WHO (World Health Organization) proposed criteria. There was CD2 þ CD3 þ CD4 -CD8 þ and T-cell receptor (TCR) ab þ LGL lymphocytosis (3.6-6.5 Â 10 9 /l). Clonal rearrangement of the TCR g-gene was detectable by polymerase chain reaction (PCR) 3 in two cases. The clinicopathologic features and treatment outcome are shown in Table 1 . Patient 1 underwent splenectomy for relief of left upper quadrant pain, followed by treatment with fludarabine and dexamethasone, mitoxantrone being omitted because of age. Patients 2 and 3 were treated with FND. Six courses were delivered as planned. During treatment, WHO grade 3 neutropenia developed in two patients, but sepsis did not Abbreviations: ANC, absolute neutrophil count ( Â 10 9 /l); CR, complete remission, defined as normalization of blood counts and marrow, and total resolution of clinical symptoms and organomegaly; FND, fludarabine, mitoxantrone and dexamethasone; Hb, hemoglobin (g/dl); HZ, herpes zoster.
LGL, large granular lymphocyte ( Â 10 9 /l); m, time from diagnosis in months; MR, molecular remission, defined as negative polymerase chain reaction (PCR) for T-cell receptor (TCR)-g gene rearrangement; NA, not applicable because TCR-g gene rearrangement was not detectable by the primers of the PCR employed; Plat, platelet count ( Â 10 9 /l); PRCA, pure red cell aplasia, defined as anemia with reticulocytopenia and less than 5% erythroid precursors in the marrow; WBC, white blood cell ( Â 10 9 /l); T-LGL, T-cell LGL.
Letters to the Editor occur. Grade 3 to 4 thrombocytopenia was not observed. All patients attained complete remission (CR). In the two cases where the leukemic clone was detectable by the primers employed in the PCR, molecular remission (MR) was also reached. Without further additional treatment, all patients had remained in CR/MR after a median follow-up of 36 (12-40) months.
These observations represent an advance in the treatment of T-LGL leukemia. The advantages of FND are a brief period of treatment (6 months), mild and acceptable toxicities, a high response rate and the important potential of inducing durable remission without maintenance medication.
We combined fludarabine with mitoxantrone and dexamethasone to maximize therapeutic efficacy, because in other lymphoproliferative diseases, fludarabine is less active as a single agent than in combinations with other drugs. Also, fludarabine had been reported to ameliorate the cytopenias associated with T-LGL leukemia, without eradicating the leukemic clone. 4 Furthermore, fludarabine alone or combined with cyclophosphamide was reported to induce only partial remissions in T-LGL leukemia. 5 Patient 1 in our study achieved a durable remission without mitoxantrone, a response indistinguishable from cases 2 and 3 achieving CR with FND. Hence, fludarabine and dexamethasone appear to be key components. 
